GTHX G1 Therapeutics: Earnings per share for the last 12 months

G1 Pharma (GTHX) - corporate logo

Slow sales of Cosela and a liquidity shortage are putting pressure on the margins of G1 Therapeutics, Inc. (GTHX). The ttm YoY earnings per share trend captures the business's adaptation, where the value of 60.30 determines the status of the profitability parameter. The team is currently optimizing licensing payments while implementing CDK4/6 inhibitors to protect patients' bone marrow during chemotherapy.

G1 Pharma (GTHX) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

GTHX (G1 Pharma): analytical breakdowns and indicator data

- price and consensus price forecast:
- company stock capitalization data:
Fundamental company valuation:GTHX G1 Therapeutics, Inc.
Flagship merchandise of G1 Therapeutics Inc.

The indicator is calculated as the percentage change in net earnings per share over a rolling 12-month period, reflecting capital sensitivity to operating results. This metric determines the actual speed of business recovery and the pace of overcoming crisis phases. For G1 Therapeutics, Inc. (GTHX), this serves as a marker for the commercialization efficiency of CDK4/6 inhibitors. The relative YoY EPS growth over the last 12 months demonstrates how successfully the patient immunity protection strategy is being converted into shareholder value.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Silexion (SLXN)|Earnings per share for the last twelve months nucana.com|CMRX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CYCC|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months